Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma

Fudan University

Status and phase

Unknown

Phase 2

Conditions

Unresectable

Hepatocellular Carcinoma

Treatments

Drug: Songyou

Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT00805896

LCI-1001

Details and patient eligibility

About

Songyou Granule is a mixture of 6 herbs. Vitro and vivo studies showed that Songyou Granule can inhibit HCC cells grow, and HCC metastasis. Hypothesis of this study is that TACE plus Songyou Granule will improve outcome in patients with advanced hepatocellular carcinoma (HCC) compared with TACE.

Full description

Primary outcome Measures:

To evaluate the effect of TACE plus Songyou Granule or TACE plus placebo on TTP

Secondary Outcome Measures:

Overall survival (OS)
Progression Free Survival (PFS)
The overall response rate
Time to symptomatic Progression
In an exploratory manner the relative TTP, TTSP, RR and overall survival between the 2 study populations
Overall response duration and time to objective response
Overall disease control rate
The safety, tolerability, and adverse event profiles of the two treatment regimens used in this trial

Enrollment: 260 Study Start Date: January 2009 Study Completion Date: December 2010 Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)

Enrollment

260 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults patients (≥ 18 years of age) with a diagnosis of HCC which is not amenable to surgical resection or local ablative therapy
Histological confirmed HCC or clinical/laboratory diagnosis of HCC or nodules larger than 2 cm with typical vascular features or AFP > 200
Patient must have quantifiable disease limited to the liver
Patients must have at least one tumor lesion that meets both of the following criteria:
- The lesion can be accurately measured in at least one dimension according to RECIST criteria
- The lesion has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
ECOG performance status (PS) <2
No prior targeted antiangiogenic therapy. Metronomic chemotherapies are allowed. At least 4 weeks since prior systemic chemotherapy
No significant baseline liver dysfunction. Cirrhotic status of Child-Pugh class A or B
No significant renal impairment (creatinine clearance < 30 mL/minute) or patients on dialysis
The following laboratory parameters:
- Platelet count ≥ 50,000/µL
- Hemoglobin ≥ 8.5 g/dL
- Total bilirubin ≤ 2 mg/dL
- ASL and AST ≤ 5 x upper limit of normal
- Serum creatinine ≤ 1.5 x upper limit of normal
- INR ≤ 1.5 or a PTT within normal limits
Ability to understand the protocol and to agree to and sign a written informed consent document

Exclusion criteria

Previous or concurrent cancer that is distinct in primary site or histology from HCC except cervical carcinoma in situ, treated basal-cell carcinoma of the skin, superficial bladder tumors (Ta, Tis & T1), and any cancer curatively treated > 3 years prior to entry is permitted
Renal failure requiring hemo- or peritoneal dialysis
Child-Pugh C hepatic impairment
Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
Known central nervous system tumors including metastatic brain disease
History of organ allograft
Substance abuse (current), psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
Known or suspected allergy to the investigational agents or any agent given in association with this trial.
Patients unable to swallow oral medications.
Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of the study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.